GSK PLC (GSK.L) Thursday said its Phase 3 DREAMM-8 study in relapsed or refractory multiple myeloma met its primary goal of progression-free survival in an interim analysis.
The DREAMM-8 phase III clinical trial was to evaluate Blenrep, in combination with PomDex, versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.
The Blenrep combination significantly extended the time to disease progression or death versus the standard of care combination. The trial was unblinded early based on the recommendation by an Independent Data Monitoring Committee (IDMC), GSK said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.